Calidi Biotherapeutics (CLDI) Profit After Tax (2022 - 2026)

Calidi Biotherapeutics' Profit After Tax history runs 4 years deep, the most recent figure standing at -$3.9 million for Q4 2025.

• In Q4 2025, Profit After Tax rose 5.93% year-over-year to -$3.9 million; the TTM figure through Dec 2025 stood at -$19.9 million (up 10.37% YoY), while the FY2025 annual figure was -$19.9 million, up 10.37% from the prior year.
• Profit After Tax for Q4 2025 stood at -$3.9 million, up from -$5.2 million in the prior quarter.
• The five-year high for Profit After Tax was -$2.0 million in Q3 2023, with the low at -$12.5 million in Q2 2023.
• The 4-year median for Profit After Tax is -$5.6 million (2022), against an average of -$6.0 million.
• Peak annual rise in Profit After Tax reached 62.2% in 2023, while the deepest fall reached 173.19% in 2023.
• Calidi Biotherapeutics' Profit After Tax stood at -$7.8 million in 2022, then fell by 6.1% to -$8.2 million in 2023, then jumped by 49.59% to -$4.1 million in 2024, then advanced by 5.93% to -$3.9 million in 2025.
• Business Quant data shows CLDI's Profit After Tax at -$3.9 million in Q4 2025, -$5.2 million in Q3 2025, and -$5.8 million in Q2 2025.